Development of a Cell Line for ILTV Vaccine Production - Formerly PRJ-010654

Infectious Laryngotracheitis Virus (ILTV) is causing significant commercial burden to the Australian poultry industry. Emergence of more virulent strains of ILTV from the recombination of attenuated vaccine strains has added significant pressure to the control of this disease. A safe and effective ILTV vaccine offers possible control mechanism for ILTV, however, production relies on the use of eggs that is expensive and time consuming and results in extremely low yields leading to a shortfall in vaccine supply. This investment targets the development of a cell line substrate with enhanced ILTV growth properties to allow vaccine generation without the reliance on the egg production method